Iterative Scopes Announces $150 Million Series B to Advance AI-Driven Precision Medicine for Gastroenterology

With this investment round, we are relentless in our drive towards narrowing disparities in patient outcomes through the use of artificial intelligence, starting with inflammatory bowel disease and colorectal cancer,” said Iterative Scopes Founder and CEO Jonathan Ng. “Patients experiencing new and chronic gastrointestinal problems have been underserved by the technology available today,” said Lonne Jaffe, Managing Director at Insight Partners, who is joining Iterative Scopes’ board. “Harnessing the power of artificial intelligence, Iterative Scopes’ formidable technology is designed to enhance gastrointestinal patient care by making it easier and quicker than ever for physicians to interpret test results and diagnose issues. Iterative Scopes is a pioneer in the application of artificial intelligence-based precision medicine for gastroenterology with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD). Insight Partners is a leading global venture capital and private equity firm investing in high-growth technology and software ScaleUp companies that are driving transformative change in their industries.